BACKGROUND: It is unclear whether patients undergoing trimodality therapy (TMT) should be screened or surveyed for brain metastases. METHODS: We retrospectively analyzed esophageal cancer (EC) patients who underwent TMT between the years 2000 and 2010. All were systematically staged and surveyed but none had screening or surveillance brain imaging. RESULTS: The median follow-up time for 518 patients was 29.3 months (range 1-149.2); all patients had adenocarcinoma of the esophagus. Of 188 (36.3%) patients who developed distant metastases, 20 (10.6% of 188 patients or 3.9% of 518 patients) had brain metastases. A higher baseline clinical stage (stage III or IVa) was associated with brain metastases. Most (90%) patients with brain metastases were diagnosed within 24 months of surgery. Sixteen patients had central nervous system symptoms at diagnosis. Twelve (60%) patients had solitary metastasis and 8 (40%) patients had multiple metastases. Although 17 patients received therapy for brain metastases, the median overall survival time of 20 patients was only 10.5 months (95% CI 6.6-14.0). CONCLUSION: After TMT, 3.9% of EC patients developed brain metastases and their prognosis was poor. Our data suggest that screening and/or surveillance for brain metastases in the EC population undergoing TMT is not warranted.
BACKGROUND: It is unclear whether patients undergoing trimodality therapy (TMT) should be screened or surveyed for brain metastases. METHODS: We retrospectively analyzed esophageal cancer (EC) patients who underwent TMT between the years 2000 and 2010. All were systematically staged and surveyed but none had screening or surveillance brain imaging. RESULTS: The median follow-up time for 518 patients was 29.3 months (range 1-149.2); all patients had adenocarcinoma of the esophagus. Of 188 (36.3%) patients who developed distant metastases, 20 (10.6% of 188 patients or 3.9% of 518 patients) had brain metastases. A higher baseline clinical stage (stage III or IVa) was associated with brain metastases. Most (90%) patients with brain metastases were diagnosed within 24 months of surgery. Sixteen patients had central nervous system symptoms at diagnosis. Twelve (60%) patients had solitary metastasis and 8 (40%) patients had multiple metastases. Although 17 patients received therapy for brain metastases, the median overall survival time of 20 patients was only 10.5 months (95% CI 6.6-14.0). CONCLUSION: After TMT, 3.9% of EC patients developed brain metastases and their prognosis was poor. Our data suggest that screening and/or surveillance for brain metastases in the EC population undergoing TMT is not warranted.
Authors: Kazuto Harada; Hyunsoo Hwang; Xuemei Wang; Ahmed Abdelhakeem; Masaaki Iwatsuki; Mariela A Blum Murphy; Dipen M Maru; Brian Weston; Jeffrey H Lee; Jane E Rogers; Allison Trail; Namita Shanbhag; Meina Zhao; Manoop S Bhutani; Quynh-Nhu Nguyen; Stephen G Swisher; Naruhiko Ikoma; Prajnan Das; Wayne L Hofstetter; Brian D Badgwell; Jaffer A Ajani Journal: Gastric Cancer Date: 2020-04-28 Impact factor: 7.370
Authors: Nishi Kothari; Eric Mellon; Sarah E Hoffe; Jessica Frakes; Ravi Shridhar; Jose Pimiento; Ken Meredith; Nam D Tran; Nadia Saeed; Khaldoun Almhanna Journal: J Gastrointest Oncol Date: 2016-08
Authors: J Feilchenfeldt; Z Varga; M Siano; H I Grabsch; U Held; B Schuknecht; A Trip; T Hamaguchi; P Gut; O Balague; K Khanfir; J Diebold; W Jochum; H Shoji; R Kushima; D Wagner; Y Shimada; A Cats; A Knuth; H Moch; S Aebi; S Hofer Journal: Br J Cancer Date: 2015-08-27 Impact factor: 7.640
Authors: Johannes Lemke; Jan Scheele; Thomas Kapapa; Silvia von Karstedt; Christian Rainer Wirtz; Doris Henne-Bruns; Marko Kornmann Journal: Int J Mol Sci Date: 2014-09-22 Impact factor: 5.923
Authors: Marius Brunner; Dominik Soll; Kathrin Adler; André Sasse; Ute König; Ardian Mekolli; Kristina Lowes; Johanna Reinecke; Volker Ellenrieder; Alexander König Journal: Gastric Cancer Date: 2021-07-23 Impact factor: 7.370